Ventripoint Diagnostics Valuation
Is VPT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of VPT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate VPT's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate VPT's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VPT?
Key metric: As VPT barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is VPT's PB Ratio? | |
|---|---|
| PB Ratio | -10.7x |
| Book | -CA$2.05m |
| Market Cap | CA$21.05m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 304.4x |
| Enterprise Value/EBITDA | -4.4x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does VPT's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.3x | ||
NSCI Nanalysis Scientific | 1.8x | n/a | CA$41.8m |
THRM Therma Bright | 7.3x | n/a | CA$11.1m |
ASG Aurora Spine | 4.9x | n/a | CA$34.8m |
PINK Perimeter Medical Imaging AI | 3.1x | -12.3% | CA$57.9m |
VPT Ventripoint Diagnostics | n/a | n/a | CA$21.0m |
Price-To-Book vs Peers: VPT has negative equity and a Price-To-Book Ratio (-10.7x) compared to the peer average (4.3x).
Price to Book Ratio vs Industry
How does VPT's PB Ratio compare vs other companies in the CA Medical Equipment Industry?
Price-To-Book vs Industry: VPT has negative equity and a Price-To-Book Ratio (-10.7x) compared to the North American Medical Equipment industry average (2.7x).
Price to Book Ratio vs Fair Ratio
What is VPT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -10.7x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate VPT's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
NeuPath Health
CA$9.6m
Provides chronic pain management services in Canada.
NPTH
CA$0.16
7D
-5.9%
1Y
-5.9%
Hamilton Thorne
CA$344.7m
Develops, manufactures, and sells precision instruments, laboratory equipment, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets.
HTL
CA$2.24
7D
0%
1Y
79.2%
Medical Facilities
CA$362.7m
Through its subsidiaries, owns and operates specialty hospitals and ambulatory surgery center in the United States.
DR
CA$15.87
7D
0%
1Y
83.9%